PT830859E - Copolimeros de poliesteres como matrizes de fornecimento de farmacos - Google Patents

Copolimeros de poliesteres como matrizes de fornecimento de farmacos

Info

Publication number
PT830859E
PT830859E PT97202533T PT97202533T PT830859E PT 830859 E PT830859 E PT 830859E PT 97202533 T PT97202533 T PT 97202533T PT 97202533 T PT97202533 T PT 97202533T PT 830859 E PT830859 E PT 830859E
Authority
PT
Portugal
Prior art keywords
matrices
polyester copolymers
pharmacy supply
pharmacy
supply
Prior art date
Application number
PT97202533T
Other languages
English (en)
Inventor
Clemens Antoni Va Blitterswijk
Wilhelmus Everhardus Hennink
Jacob Hillebrand Goedemoed
Jeroen Mattijs Bezemer
Jan Feijen
Josef Dick De Bruijn
Original Assignee
Chienna Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chienna Bv filed Critical Chienna Bv
Publication of PT830859E publication Critical patent/PT830859E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT97202533T 1996-08-16 1997-08-18 Copolimeros de poliesteres como matrizes de fornecimento de farmacos PT830859E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/699,896 US5980948A (en) 1996-08-16 1996-08-16 Polyetherester copolymers as drug delivery matrices

Publications (1)

Publication Number Publication Date
PT830859E true PT830859E (pt) 2004-04-30

Family

ID=24811379

Family Applications (2)

Application Number Title Priority Date Filing Date
PT97202533T PT830859E (pt) 1996-08-16 1997-08-18 Copolimeros de poliesteres como matrizes de fornecimento de farmacos
PT02077025T PT1247522E (pt) 1996-08-16 1997-08-18 Farmacos copolimeros de poliester como matrizes de administracao de

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT02077025T PT1247522E (pt) 1996-08-16 1997-08-18 Farmacos copolimeros de poliester como matrizes de administracao de

Country Status (9)

Country Link
US (1) US5980948A (pt)
EP (2) EP0830859B1 (pt)
AT (2) ATE255884T1 (pt)
CA (1) CA2213368C (pt)
DE (2) DE69729228T2 (pt)
DK (2) DK1247522T3 (pt)
ES (2) ES2221916T3 (pt)
PT (2) PT830859E (pt)
WO (1) WO1998006439A1 (pt)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842657A1 (en) * 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
FR2777895A1 (fr) * 1998-04-28 1999-10-29 Debio Rech Pharma Sa Polymere sequence non-reticule,procede pour sa preparation, et ses utilisations
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
US6656489B1 (en) 1999-02-10 2003-12-02 Isotis N.V. Scaffold for tissue engineering cartilage having outer surface layers of copolymer and ceramic material
EP1038538A1 (en) * 1999-03-19 2000-09-27 IsoTis B.V. Muscle tissue engineering
ATE244558T1 (de) * 1999-04-16 2003-07-15 Novo Nordisk As Trockene formbare arzneistoffformulierung
AU4518400A (en) * 1999-07-12 2001-01-18 Isotis B.V. Sutures
EP1068872A1 (en) * 1999-07-12 2001-01-17 IsoTis B.V. Sutures
WO2001010414A1 (en) * 1999-08-04 2001-02-15 Oakwood Laboratories L.L.C. Slow release microspheres
EP1902738B1 (en) * 1999-08-06 2009-12-30 Chienna B.V. Process for molding of a polymer
CA2321321A1 (en) 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
EP1090928B1 (en) * 1999-09-30 2004-05-26 Chienna B.V. Polymers loaded with bioactive agents
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
DE60127139T2 (de) * 2000-07-14 2007-12-13 Novo Nordisk A/S Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial
EP1247537A1 (en) * 2001-04-04 2002-10-09 Isotis B.V. Coating for medical devices
US6565884B2 (en) 2001-09-10 2003-05-20 Interpore Cross International Bone graft material incorporating demineralized bone matrix and lipids
US7357947B2 (en) * 2001-09-10 2008-04-15 Biomet, Inc. Bone graft material incorporating demineralized bone matrix and lipids
WO2003041689A1 (en) * 2001-11-12 2003-05-22 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
ATE335035T1 (de) * 2002-02-26 2006-08-15 Chienna Bv Bioabbaubares polymermaterial für biomedizinische anwendungen
ES2665999T3 (es) * 2002-05-31 2018-04-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para la liberación sostenida de buprenorfina
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
US6926919B1 (en) * 2003-02-26 2005-08-09 Advanced Cardiovascular Systems, Inc. Method for fabricating a coating for a medical device
PL1610791T3 (pl) 2003-03-31 2011-07-29 Titan Pharmaceuticals Inc Wszczepialne urządzenie polimerowe do przedłużonego uwalniania agonisty dopaminy
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
US20040215318A1 (en) * 2003-04-24 2004-10-28 Brian Kwitkin Timed delivery of therapeutics to blood vessels
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
JP4889505B2 (ja) 2004-02-02 2012-03-07 アンブレツクス・インコーポレイテツド 被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用
EP1789088A4 (en) * 2004-03-24 2009-12-30 Doctor S Res Group Inc METHOD FOR IMPLEMENTING MEDICAL METHODS FOR PROMOTING BONE GROWTH, METHOD FOR PRODUCING COMPOUNDS FOR PROMOTING BONE GROWTH AND DEVICE FOR USE IN SUCH PROCEDURES
EP2329852A1 (en) 2004-03-26 2011-06-08 SurModics, Inc. Composition and method for preparing biocompatible surfaces
JP2008503217A (ja) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド 新規抗原結合ポリペプチド及びそれらの使用
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
US20060018948A1 (en) * 2004-06-24 2006-01-26 Guire Patrick E Biodegradable implantable medical devices, methods and systems
WO2009100255A2 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
CA2569381A1 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7311980B1 (en) * 2004-08-02 2007-12-25 Advanced Cardiovascular Systems, Inc. Polyactive/polylactic acid coatings for an implantable device
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
GB0426823D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
GB0426822D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
WO2006068802A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
JP2008525032A (ja) * 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
US20060147491A1 (en) * 2005-01-05 2006-07-06 Dewitt David M Biodegradable coating compositions including multiple layers
US20060198868A1 (en) * 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
CA2609205A1 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
AU2005335491B2 (en) 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
ATE500215T1 (de) * 2005-11-08 2011-03-15 Ambrx Inc Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
ES2547554T3 (es) * 2005-11-16 2015-10-07 Ambrx, Inc. Métodos y composiciones que comprenden aminoácidos no naturales
WO2007061896A1 (en) 2005-11-17 2007-05-31 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
KR101423898B1 (ko) * 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
EP2037977A2 (en) * 2006-06-28 2009-03-25 SurModics, Inc. Active agent eluting matrices with particulates
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
CN101541955B (zh) * 2006-09-08 2016-09-28 Ambrx公司 用于脊椎动物细胞的杂合抑制tRNA
PT2064333E (pt) * 2006-09-08 2014-06-09 Ambrx Inc Supressor híbrido arnt para células de vertebrados
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
US20080154241A1 (en) * 2006-12-07 2008-06-26 Burkstrand Michael J Latent stabilization of bioactive agents releasable from implantable medical articles
PL2068909T3 (pl) 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
EP2076533B1 (en) 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
BRPI0811784A2 (pt) 2007-05-23 2011-05-10 Allergan Inc colÁgeno reticulado e uso do mesmo
WO2009005709A1 (en) * 2007-06-28 2009-01-08 Surmodics, Inc. Polypeptide microparticles
WO2009005718A1 (en) * 2007-06-28 2009-01-08 Surmodics, Inc. Polypeptide microparticles having sustained release characteristics, methods and uses
WO2009015336A2 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US9138509B2 (en) * 2007-09-14 2015-09-22 Musculoskeletal Transplant Foundation Composition for filling bone defects
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
EP2055299A1 (en) * 2007-10-23 2009-05-06 Koninklijke Philips Electronics N.V. Methods for preparing polymer microparticles
EP2818184B1 (en) 2007-11-16 2018-10-31 Allergan, Inc. Compositions and methods for treating Purpura
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
EP2235266A1 (en) * 2007-12-21 2010-10-06 3M Innovative Properties Company Retroreflective pavement markings
DE102007062113B4 (de) * 2007-12-21 2011-05-12 Bettina Lingenfelder Dermatologische Zubereitung
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
US20090186059A1 (en) * 2008-01-14 2009-07-23 Johnson Elizabeth E Devices and methods for elution of nucleic acid delivery complexes
WO2009120361A2 (en) 2008-03-28 2009-10-01 Surmodics, Inc. Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery
WO2009126830A2 (en) * 2008-04-09 2009-10-15 Surmodics, Inc. Delivery of nucleic acid complexes from materials including negatively charged groups
EP2265293B1 (en) * 2008-04-18 2015-11-04 SurModics, Inc. Coating systems for the controlled delivery of hydrophilic bioactive agents
JP2011518881A (ja) 2008-04-28 2011-06-30 ゾゲニクス インコーポレーティッド 片頭痛の治療のための製剤
CA2723192A1 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
US20100008966A1 (en) * 2008-07-14 2010-01-14 Surmodics, Inc. Medical Devices and Methods for Delivery of Nucleic Acids
JP5680534B2 (ja) 2008-07-23 2015-03-04 イーライ リリー アンド カンパニー 修飾されているウシg−csfポリペプチドおよびそれらの使用
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
CA2735173C (en) 2008-09-02 2017-01-10 Tautona Group Lp Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US8283165B2 (en) 2008-09-12 2012-10-09 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
PE20110832A1 (es) 2008-09-26 2011-11-24 Ambrx Inc Polipeptidos de eritropoyetina felina modificados
MX348657B (es) 2008-09-26 2017-06-21 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
US8883208B2 (en) * 2009-04-08 2014-11-11 Surmodics, Inc. Particles for delivery of nucleic acids and related devices and methods
CA2758260A1 (en) * 2009-04-08 2010-10-14 Surmodics, Inc. Controlled release devices and methods for delivery of nucleic acids
US8246576B2 (en) 2009-05-18 2012-08-21 Surmodics, Inc. Method and apparatus for delivery of a therapeutic agent with an expandable medical device
CN102666578A (zh) 2009-12-21 2012-09-12 Ambrx公司 经过修饰的猪促生长素多肽和其用途
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
US20110159098A1 (en) * 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
NZ602405A (en) 2010-03-12 2014-12-24 Allergan Ind Sas A fluid composition comprising a hyaluronan polymer and mannitol for improving skin conditions
DK2550027T4 (da) 2010-03-22 2019-05-13 Allergan Inc Tværbundne polysaccharid- og protein-polysaccharid-hydrogeler til blødvævsforøgelse
US20110319473A1 (en) 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
PL2859887T3 (pl) 2010-07-09 2017-10-31 Innocore Tech B V Biodegradowalne segmentowane kopolimery wieloblokowe z rozdziałem faz oraz uwalnianie biologicznie czynnych polipeptydów
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
CA2808596C (en) 2010-08-17 2020-12-15 Ambrx, Inc. Modified relaxin polypeptides and their uses
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
EP2621475A1 (en) 2010-10-02 2013-08-07 Link Research&Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US20120100187A1 (en) 2010-10-26 2012-04-26 Surmodics, Inc. Coatings and methods for controlled elution of hydrophilic active agents
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
US9861727B2 (en) 2011-05-20 2018-01-09 Surmodics, Inc. Delivery of hydrophobic active agent particles
FR2975301B1 (fr) * 2011-05-20 2013-05-24 Flamel Tech Sa Composition comprenant un interferon alpha
US10213529B2 (en) 2011-05-20 2019-02-26 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
EP2714002B1 (en) 2011-06-03 2019-04-03 Allergan, Inc. Dermal filler compositions including antioxidants
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
JP2014523914A (ja) 2011-07-18 2014-09-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作された微生物標的化分子およびその使用
KR101889586B1 (ko) 2011-07-22 2018-09-20 이노코어 테크놀로지스 비.브이. 생물학적 활성 화합물의 조절된 방출을 위한 생분해성, 반-결정, 상 분리, 열 가소성 플라스틱의 멀티-블록 공중합체
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
JP6498600B2 (ja) 2012-06-08 2019-04-10 ストロ バイオファーマ インコーポレーテッド 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CN104981254B (zh) 2012-08-31 2018-05-22 苏特罗生物制药公司 含有叠氮基的经修饰的氨基酸
US11246963B2 (en) 2012-11-05 2022-02-15 Surmodics, Inc. Compositions and methods for delivery of hydrophobic active agents
WO2014071387A1 (en) 2012-11-05 2014-05-08 Surmodics, Inc. Composition and method for delivery of hydrophobic active agents
WO2014167440A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Modified release pharmaceutical compositions of cyclobenzaprine or salts thereof
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
FR3007972B1 (fr) 2013-07-04 2015-08-07 Oreal Composition cosmetique comprenant des esters gras liquides, des huiles volatiles et des epaississants, et procede de traitement cosmetique
EP3019522B1 (en) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
WO2015150948A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof
WO2016040347A2 (en) 2014-09-08 2016-03-17 University Of Iowa Research Foundation Microrna inhibitor system and methods of use thereof
ES2761558T3 (es) 2014-09-30 2020-05-20 Allergan Ind Sas Composiciones de hidrogel estables que incluyen aditivos
JP6702962B2 (ja) 2014-10-24 2020-06-03 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 改変fgf−21ポリペプチドおよびその使用
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
US10531957B2 (en) 2015-05-21 2020-01-14 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
EP3331549B1 (en) 2015-08-06 2020-12-23 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
US10273476B2 (en) 2016-04-30 2019-04-30 University Of Iowa Research Foundation MicroRNA-200 based approaches for modulating bone formation inhibition and bone regeneration
RU2617049C1 (ru) * 2016-05-12 2017-04-19 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противоопухолевое лекарственное средство на основе никлозамида
US10898446B2 (en) 2016-12-20 2021-01-26 Surmodics, Inc. Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces
CN110637027A (zh) 2017-02-08 2019-12-31 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
CN112351992A (zh) 2017-12-20 2021-02-09 阿勒根公司 肉毒杆菌毒素细胞结合结构域多肽及其用于皮肤再生的方法
PL3849614T3 (pl) 2018-09-11 2024-04-22 Ambrx, Inc. Koniugaty polipeptydu interleukiny-2 i ich zastosowania
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス,インコーポレイテッド インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
JP2023517595A (ja) 2020-03-11 2023-04-26 アンブルックス,インコーポレイテッド インターロイキン-2ポリペプチド結合物およびその使用方法
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
KR20240004342A (ko) 2021-04-03 2024-01-11 암브룩스, 인코포레이티드 항-her2 항체-약물 접합체 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237885A (en) * 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
IL84167A (en) * 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
US5066772A (en) * 1987-12-17 1991-11-19 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
DE69129770T2 (de) * 1990-04-13 1998-11-19 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung
FR2671562B1 (fr) * 1991-01-16 1995-09-15 Oreal Procede de diagnostic d'un etat d'inflammation ou de vieillissement cellulaire des keratinocytes, et necessaire pour la mise en óoeuvre de ce procede.
BR9306038A (pt) * 1992-02-28 1998-01-13 Univ Texas Hidrogéis biodegradáveis fotopolimerizáveis como materiais de contato de tecidos e condutores de liberação controlada
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
EP0637229B1 (en) * 1992-04-24 2002-11-20 Osteotech, Inc., Devices for preventing tissue adhesion
DK0603992T4 (da) * 1992-12-22 2001-03-05 Univ Cincinnati Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner
JPH09500132A (ja) * 1993-07-12 1997-01-07 ヴァイラス リサーチ インスティチュート ヒドロゲルマイクロカプセル化ワクチン
ATE209907T1 (de) * 1994-04-08 2001-12-15 Atrix Lab Inc Flüssige mittel zur wirkstoffabgabe
EP0717999A1 (en) * 1994-12-19 1996-06-26 The University Of Miami Drug delivery composition

Also Published As

Publication number Publication date
EP0830859B1 (en) 2003-12-10
PT1247522E (pt) 2004-10-29
US5980948A (en) 1999-11-09
DK0830859T3 (da) 2004-04-05
EP0830859A3 (en) 1998-07-22
CA2213368C (en) 2008-04-01
ATE267006T1 (de) 2004-06-15
DE69726672D1 (de) 2004-01-22
ATE255884T1 (de) 2003-12-15
DE69729228T2 (de) 2005-05-04
WO1998006439A1 (en) 1998-02-19
CA2213368A1 (en) 1998-02-16
EP0830859A2 (en) 1998-03-25
DE69729228D1 (de) 2004-06-24
ES2212037T3 (es) 2004-07-16
DE69726672T2 (de) 2004-10-07
EP1247522A1 (en) 2002-10-09
DK1247522T3 (da) 2004-09-27
ES2221916T3 (es) 2005-01-16
EP1247522B1 (en) 2004-05-19

Similar Documents

Publication Publication Date Title
PT830859E (pt) Copolimeros de poliesteres como matrizes de fornecimento de farmacos
CA2355657A1 (en) Biodegradable ph/thermosensitive hydrogels for sustained delivery of biologically active agents
CA2304976A1 (en) Delivery of poly(ethylene glycol)-conjugated molecules from degradable hydrogels
ZA9811377B (en) Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake.
IL144398A0 (en) Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
GB2340040B (en) Microparticles useful as ultrasonic contrast agents and for delivery of drugs into the bloodstream
BR9801027B1 (pt) sistema de distribuiÇço de medicamentos.
HUP0102803A2 (hu) Hőérzékeny és biológiailag lebontható hidrogélek biológiailag aktív anyagok elnyújtott idejű felszabadulásának biztosítására
AU9617698A (en) Polymeric systems for drug delivery and uses thereof
ATE291417T1 (de) Gastrointestinales wirkstoffverabreichungssystem
EP2260872A3 (en) Polymer conjugates of interferon beta-1A and uses thereof
DK1037667T3 (da) Farmaceutiske hydrogelformuleringer, lægemiddelindgivelsesanordninger samt fremgangsmåder
DE69001876T2 (de) Hoch-resorbierbare transvaginale Zubereitung mit biologisch aktiven Peptiden.
EP1021168A4 (en) MICRO AND NANOAPARTICULAR, POLYMERIC ADMINISTRATION SYSTEM
BR9812553B1 (pt) formulação medicamentosa em pélete de difusão controlada e em um sistema matriz.
BR9810285A (pt) Solução, composição farmacêutica, e, cápsula de gelatina.
DE69727204D1 (de) Lösungsabgabesystem mit individueller, integrierter endverpackung und zugehöriges verpackungsverfahren
ES1010911Y (es) Modulo de distribucion y entrega.
AU2002251955A1 (en) Biodegradable cationic copolymers of poly(alkylenimine) and poly(ethylene glycol) for the delivery of bioactive agents
KR940007408U (ko) 메세지 전달 카드
ZA974920B (en) Drug delivery systems.
DK1304105T3 (da) Implanterbart diffusionsafleveringssystem